Analysts expect Stryker’s Q4 to deliver resilient procedure volume growth and robust capital equipment demand driven by strong product momentum and broad-based segment strength. Hospital end-market demand and product launches across orthopedic and neurotechnology lines underpin anticipated capital spending.